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Background. Tonsils play a key role in eliciting immune responses against respiratory pathogens. Little is known about how
tonsils contribute to the local immune response after intranasal vaccination. Here, we uniquely report the mucosal humoral respons-
es in tonsils and saliva after intranasal live attenuated influenza vaccine (LAIV) vaccination in children.
Methods. Blood, saliva, and tonsils samples were collected from 39 children before and after LAIV vaccination and from 16 age-
matched, nonvaccinated controls. Serum antibody responses were determined by a hemagglutination inhibition (HI) assay. The sali-
vary immunoglobulin A (IgA) level was measured by an enzyme-linked immunosorbent assay. Antibody-secreting cell (ASC) and
memory B-cell (MBC) responses were enumerated in tonsils and blood.
Results. Significant increases were observed in levels of serum antibodies and salivary IgA to influenza A(H3N2) and influenza B
virus strains as early as 14 days after vaccination but not to influenza A(H1N1). Influenza virus–specific salivary IgA levels correlated
with serum HI responses, making this a new possible indicator of vaccine immunogenicity in children. LAIV augmented influenza
virus–specific B-cell responses in tonsils and blood. Tonsillar MBC responses correlated with systemic MBC and serological respons-
es. Naive children showed significant increases in MBC counts after LAIV vaccination.
Conclusions. This is the first study to demonstrate that LAIV elicits humoral B-cell responses in tonsils of young children. Fur-
thermore, salivary IgA analysis represents an easy method for measuring immunogenicity after vaccination.
Keywords. pediatric; influenza; LAIV; lymphoid tissue; tonsils; mucosa; saliva immune response; humoral; memory B cell;
antibody-secreting cell; longevity.
Influenza continues to be an important infectious disease, with
annual epidemics claiming up to half a million lives and causing
a significant economic burden [1]. Annual seasonal immuniza-
tion with inactivated trivalent influenza vaccine (TIV) is the
most widely used and cost-effective measure for limiting the
impact of influenza. An alternative vaccination strategy is to
use live attenuated influenza vaccine (LAIV), which was li-
censed in Europe for children (2–17 years old) in 2012 [2].
LAIV is genetically stable and attenuated to have limited repli-
cation in the upper respiratory tract. Meta-analysis of LAIV ef-
ficacy studies have demonstrated up to 80% efficacy to matched
strains in children <6 years old and 40% efficacy in adults [3–5].
However, the immunological mechanisms and correlates of
protection of LAIV are not yet clearly understood.
Serum antibody levels are known to underestimate the pro-
tection achieved by LAIV [6]. Other immunological mecha-
nisms are thought to be involved in conferring protection
after intranasal immunization, and mucosal responses warrant
further investigation. Tonsils are local lymph nodes serving the
upper respiratory tract and are a collection of mucosa-associated
lymphoid tissues. They consist of a pharyngeal (adenoid) and
lingual tonsil and 2 tubal and palatine tonsils (referred to as ton-
sils). Tonsils play a key role in eliciting mucosal immune respons-
es against respiratory pathogens [7], but their role in eliciting
immune response against antigens delivered by intranasal vacci-
nation is not widely reported.
Delivery of LAIV via the intranasal route is perhaps the most
efficient way of boosting mucosal immunity at the site of viral
entry and induces a weaker systemic response as compared to
that of TIV [8]. The tonsil’s location at the site of entry into
the upper respiratory tract suggests a major role in anti-influenza
immunity. The tonsillar epithelium is composed of deep crypts
to maximize the surface area exposed to antigens, with Langer-
hans and M cells transporting luminal antigens into the tonsillar
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tissue [9, 10]. Evidence suggests that tonsils have functional T
cells and can provide B cells for mucosal effector sites, including
upper airway mucosa and lacrimal and salivary glands [11, 12].
In this unique study, we have vaccinated young children with
LAIV at specific time points prior to elective tonsillectomy. We
aimed to characterize the early local immune responses after
LAIV vaccination, using the blood, saliva, and tonsils obtained
from these children. We have previously reported that the sys-
temic B- and T-cell responses persisted for 1 year after LAIV
vaccination in some children [13]. Here we show that the
LAIV induces early salivary antibody and B-cell responses in




Fifty-five healthy children (3–17 years old) scheduled for tonsil-
lectomy were recruited from outpatients at the ear, nose, and
throat (ENT) clinic at Haukeland University Hospital (Figure 1).
Thirty-nine children were vaccinated with trivalent LAIV (Flu-
enz, Astra Zeneca, United Kingdom) during the influenza season
from October 2012 to February 2013. The study had ethical and
regulatory approval (clinical trials registration NCT01866540).
Exclusion criteria have been published previously [13].
To study the early immunological responses after LAIV, we
chose the earliest time point that was considered safe by the
anesthesiologist (day 3), in addition to 1 and 2 weeks after
vaccination. The sampling days were based around the distribu-
tion of antibody-secreting cells (ASCs) in peripheral blood, the
levels of which peak around day 7 after vaccination, but they
have been observed as early as day 2 after TIV vaccination
[14–16]. The children were randomized into 3 subgroups, de-
pending on scheduled tonsillectomy date: 3–5 days (n = 10), 7
days (range, 6–9 days; n = 13), and 14 days (range, 11–20 days;
n = 16) after vaccination. The number of children was obtained
from asking eligible children set up for elective tonsillectomy
during the vaccination period. A nonvaccinated control group
consisted of 16 age-matched children as a prevaccination com-
parator for the tonsillar responses in the vaccinated children;
the controls were recruited in parallel to the study subjects.
Samples were collected at a single time point during the opera-
tion (Table 1). Blood and saliva specimens were only used to
show the suitability of the controls, as prevaccination (day 0)
blood and saliva samples were collected from the vaccinated
children for comparison with samples obtained at subsequent
time points up to 180 days after vaccination.
Vaccine
LAIV was administered intranasally as a 0.1-mL spray dose into
each nostril. LAIV contained 107 fluorescent focus units of A/Cal-
ifornia/7/2009(H1N1)pdm09, A/Victoria/361/2011(H3N2), and
B/Wisconsin/1/2010. Children <10 years of age (n = 28) were
given 2 doses of LAIV as per themanufacturer’s recommendations.
None of the children had earlier received LAIV, as it was not
licensed in Norway in 2012–2013. Most children were born after
Figure 1. Study design and sample collection. Children scheduled for tonsillectomy were recruited from outpatients at the ear, nose, and throat clinic at Haukeland Uni-
versity Hospital during the influenza season of October 2012–February 2013. Control children were recruited in parallel throughout the study from the same patient population
(ie, if the parents were willing for their child to join the study but did not wish for their child to receive the live attenuated influenza vaccine). Asterisks denote nonvaccinated
controls. One control did not provide a sufficient saliva sample owing to dry mouth prior to operation. The hash indicates that 1 vaccinated child provided samples on the day of
tonsillectomy but no sample on day 0. aOnly children aged <10 years old required 2 doses of LAIV. Two children aged <10 years did not receive a second dose, 1 child was sick
on the day of the second vaccination, and another child withdrew from the study due to postoperative discomfort. bThe patients had both of their tonsils removed in 1 operation,
and therefore tonsils were only sampled at a single time point. Nonvaccinated controls were used as a prevaccination (day 0) comparator for tonsillar samples. Tonsils were
collected from vaccinated children at 3–5 days, 7 days (range, 6–9 days), or 14 days (range, 11–20 days) after vaccination. Serum and saliva samples were collected at multiple
time points from each vaccinated subject and at only a single time point, at the time of tonsillectomy, from the nonvaccinated controls. The exclusion criteria and study details
for this clinical trial have been published earlier [13].











the pandemic, and the only influenza vaccine the older children
had received was the monovalent, adjuvanted pandemic influen-
za A(H1N1) vaccine in 2009 (6 controls and 21 vaccinees).
Samples
Peripheral blood samples (8 mL) were collected at day 0 and after
vaccination, using CPT tubes (BD), and peripheral blood mono-
nuclear cells (PBMCs) and plasma were separated [17]. Plasma
samples were stored at−80°C. Immediately following tonsillecto-
my, whole tonsils were collected to isolate the tonsillar mononu-
clear cells (TMCs) by Lymphoprep (Stemcell tech, United
Kingdom). Saliva samples were absorbed from the lower buccal
mucosa for 2 minutes, using a swab (Salimetrics). The swabs
were placed in a tube and kept on ice until centrifuged (at
600 × g for 10 minutes at 4°C) before storage at −80°C.
Serological Assays
Hemagglutination Inhibition (HI) Assay
Plasma samples from each subject were tested at the same time,
in duplicate. In the HI assay, 8 hemagglutinin units of the
homologous influenza A(H1N1) and influenza A(H3N2)
virus strains or ether-treated influenza B virus vaccine strains
(50 µL/well) were used, and 0.7% turkey red blood cells, with
receptor destroying enzyme–treated serum at a starting dilution
of 1:10 [18]. The influenza virus antigens were either provided
by the WHO Influenza Reagent Resources or were grown in
eggs in our laboratory.
B-Cell Assays
The influenza virus–specific immunoglobulin G (IgG), immu-
noglobulin A (IgA), and immunoglobulin M (IgM) ASC [19]
and memory B-cell (MBC) [20] responses were determined
by an enzyme-linked immunospot (ELISPOT) assay using
fresh lymphocytes from blood and tonsils. Results are presented
as influenza virus–specific ASCs or MBCs per 1 × 106 PBMCs/
TMCs.
Salivary IgA
The concentration of influenza virus–specific IgA antibodies in
the saliva was measured in ELISA plates coated with 2 µg/mL of
split influenza virus antigens (A(H1N1), A(H3N2), or B strains)
as previously described [14].
Statistical Analysis
Statistical analysis was performed using GraphPad Prism, ver-
sion 6, for Mac OS X. Differences between prevaccination and
postvaccination ASC and MBC responses were analyzed by
matched-paired signed rank t test, (Wilcoxon), and the P
value was adjusted accordingly (by the Bonferroni method).
The comparison of HI and saliva IgA responses over time
were evaluated by analysis of variance, (nonparametric,
Kruskal–Wallis) with the Dunn multiple comparisons test. Cor-
relation analysis was performed by nonparametric Spearman
correlation. A P value of < .05 was considered statistically
significant.
Table 1. Demographic and Clinical Characteristics of the Study Children
Characteristic All Subjects, Value
Vaccinated Subjects
Control Subjects, ValueOverall Day 3–5 Day 6–9 Day 14
Subjects 55 (100) 39a (100) 9a 13 16 16 (100)
Sex
Male 28 (51) 20 (51) 6 7 6 8 (50)
Female 27 (49) 19 (49) 3 6 10 8 (50)
Age, y
3–4 31 (56) 23 (59) 6 8 8 8 (50)
5–9 15 (27) 8 (20.5) 2 3 3 7 (44)
10–17 9 (16) 8 (20.5) 1 2 5 1 (6)
Weight, kg, median (range) 19 (9–81) 19 (13–81) 18.5 (14–81) 19.3 (13–60) 19.4 (13–61) 19 (9–64)
Height, cm, median (range) 107 (88–177) 107 (88–177) 104.2 (99–176) 108.4 (95–171) 105.9 (88–172) 100 (91–164)b
A(H1N1)pdm09c vaccination 26 (47) 21 (54) 3 7 4 6 (38)d
Reason for tonsillectomye
Only recurrent tonsillitis 11 8 3 2 2 3
Only hypertrophyf 20 13 5 4 4 7
Both reasons 22 16 1 6g 9g 6
Data are no. (%) of children, unless otherwise indicated. Thirty-nine subjects received 1 dose of live attenuated influenza vaccine, and 28 children received 2 doses. Ten subjects did not receive
the second dose owing to age (8 subjects were >10 years old), illness on the day of the second dose (1 subject), and postoperative discomfort and later withdrawal from study (1 subject).
a One child had the operation delayed, therefore no samples were collected at the day of tonsillectomy, but the rest of the time points were collected.
b Data for 4 subjects are missing.
c Vaccination with 2009 pandemic influenza A(H1N1) vaccine (Pandemrix) in 2009.
d Data for 5 subjects are missing.
e Data for 2 subjects on reason for tonsillectomy are missing.
f Defined as hypertrophy-related problems such as sleep apnea/snoring, speech impairment, and recurrent ear infections.
g Data for a subject is missing.













Fifty-five healthy children were enrolled in the study during the
influenza season from October 2012–January 2013. Of these, 39
were vaccinated with LAIV, and 16 were nonvaccinated controls.
The vast majority (32 of 39) were ethnic Norwegian caucasian in-
dividuals. Among the vaccinated children, there were 20 boys and
19 girls, with a median age of 4 years (range, 3–17 years). The chil-
dren were vaccinated at 3 days (range, 3–5 days; n = 10), 7 days
(range, 6–9 days; n = 13), or 14 days (range, 11–20 days; n = 16)
prior to tonsillectomy, to allow evaluation of early tonsillar B-cell
responses after LAIV vaccination. The demographic characteris-
tics and vaccination history were similar in the 3 subgroups and
controls (Table 1). Sequential blood samples were collected before
vaccination, on the day of tonsillectomy, and 28, 56 and 180 days
after vaccination (Figure 1) [13]. The median sampling time point
was close to the target sampling day. For comparison of differenc-
es in kinetics in blood and tonsils, the early time points (days 3, 7,
and 14) were used, while the later time points were used to study
the duration of the systemic and salivary responses after LAIV
vaccination. For the comparison of background prevaccination
tonsillar responses and the responses in vaccinated children, 16
matched, nonvaccinated controls were used.
Among the 39 vaccinated children, 21 (54%) had received the
inactivated, monovalent influenza A(H1N1) pandemic vaccine
in 2009. Two vaccinees (5%) were born to mothers who had
been immunized with the pandemic vaccine during pregnancy.
Apart from 1 child, none had earlier received seasonal TIV or
LAIV, as routine influenza vaccination of children is not recom-
mended in Norway.
Serological Responses
An HI titer of ≥40 is considered protective against seasonal in-
fluenza [21]. No significant changes were observed in the post-
vaccination response against influenza A(H1N1) virus, with
45%–82% having titers of ≥40 after LAIV vaccination (Fig-
ure 2A). Significant increases in influenza B and influenza A
(H3N2) virus antibody responses were observed from 14 and
28 days after vaccination, respectively, and maintained until
day 180 (Figure 2B and 2C). Overall, the percentage of subjects
with HI titers of ≥40 against influenza A(H3N2) virus increased
from 49% at day 0 (geometric mean titer [GMT], 36) to 94% in
the group that underwent tonsillectomy 14 days after vaccina-
tion (GMT, 137; Figure 2B) and was maintained until 180 days.
The majority (89%) of children had no detectable antibodies to
the influenza B virus strain before vaccination. As early as 14
days after vaccination, 69% had protective antibody titers, in-
creasing to 76% and 84% at days 28 and 56 (P = .0001; Fig-
ure 2C). The nonvaccinated controls had similar antibody
titers to the prevaccination (day 0) titers, justifying their use
as a day 0 comparator for tonsillar responses (Figure 2; con-
trols/day 0). When studying the individual responses, no in-
crease in titers was observed on day 3, but increases were
observed in 2 children on day 7 (influenza A(H3N2) and B
virus strains), and in 10 children at day 14 (71%) for the influ-
enza B virus strain (Supplementary Figure 2). A boost after the
second dose was observed in 1 child (for influenza A(H1N1)
virus), 7 children (for influenza A(H3N2) virus), and 11 chil-
dren (for the influenza B virus strain), with the strongest re-
sponses in the unprimed children. There were no significant
differences in responses over time in the 3 groups, except at
the time of tonsillectomy (Supplementary Figure 2).
IgA Response in Saliva
Figure 3A–3C shows the influenza virus–specific IgA response
in saliva after LAIV vaccination. Significant increases (P < .001)
in saliva IgA response were detected against influenza B virus
and influenza A(H3N2) virus strains from 0 to 14 days after
vaccination and also at days 56 and 180 for the influenza B
virus strain. The IgA response was maintained to day 180
Figure 2. Serological response after live attenuated influenza vaccine (LAIV) vaccination. Plasma was collected from nonvaccinated controls (open circles) and LAIV recip-
ients (closed circles), and the serological antibody response was investigated by a hemagglutination inhibition (HI) assay. The data indicate influenza A(H1N1) virus–specific (A),
influenza A(H3N2) virus–specific (B), and influenza B virus–specific titers (C). Each symbol represents an individual subject, and the horizontal lines represent the geometric
mean titers ± 95% confidence intervals. The dotted lines represents an HI titer of 40, considered indicative of a protective level. Statistical significance between prevaccination
and postvaccination responses was measured by the nonparametric Kruskal–Wallis multiple comparisons test. **P≤ .01, ***P≤ .001, and ****P≤ .0001.











above prevaccination levels for the influenza A(H3N2) and B
virus strains. However, no significant increase in IgA responses
was observed against the influenza A(H1N1) virus strain at any
time point after vaccination. Furthermore, there was a signifi-
cant positive correlation between the postvaccination (day 3–
14), salivary IgA titers and the serum HI responses for all 3
strains (r = 0.37–0.48; P < .05). The controls had titers that
matched the prevaccination titers of the vaccinated children.
ASC Responses in Tonsils and Blood
As tonsils could only be collected at a single time point, nonvac-
cinated control children were included to show background pre-
vaccination tonsillar B-cell responses (Figure 1 and Table 1).
Serological and salivary IgA titers (Figures 2 and 3) observed
in controls were similar to the prevaccination (day 0) samples
from the vaccinated children, making them suitable for compar-
ison in the ASC and MBC assays. Influenza virus–specific ASC
responses in blood and tonsils were analyzed by ELISPOT to a
mixture of the 3 vaccine strain antigens (influenza A(H1N1),
A(H3N2), and B virus strains; Figure 4A–4F ). The antigen-
specific ASC response in TMCs was dominated by IgM and in-
creased significantly 7 days after vaccination (Figure 4C). There
were low numbers of IgG and IgA ASCs detected in the tonsils,
with the highest responses on day 14 after vaccination, com-
pared with control responses (Figure 4A and 4B).
Figure 4D–4F shows the influenza virus–specific ASC re-
sponse in PBMCs, with very low numbers detected before
and 3 days after vaccination but with significant increases in
IgG and IgA ASCs on days 7 and 14 (Figures 4D and 4E ).
IgM also increased although not significantly. At day 28, the
IgA and IgM frequencies were similar to prevaccination levels
(mean, 3 and 4 ASCs/1 × 106 PBMCs, respectively). We found
a significant positive correlation between influenza virus–
specific IgG ASC frequencies detected in tonsils and blood
after LAIV vaccination (r = 0.51; P = .007), suggesting that pe-
ripheral ASCs reflect the local tonsillar response.
MBC Responses in Tonsils and Blood
Influenza virus–specific MBC responses were detected by ELI-
SPOT in blood and tonsils. No significant increases were ob-
served in short-term MBC responses in peripheral blood or
tonsils up to day 14 (Supplementary Figure 1). In general,
much higher frequencies of IgG and IgM MBCs were detected,
compared with IgA, in both tonsils and blood.
We observed a significant positive correlation between the IgG
MBC responses in the TMCs and PBMCs to the 3 LAIV strains
(r = 0.82–0.59; P < .05). A significant positive correlation was also
detected between the IgG MBC responses in the TMCs and the
HI responses at the corresponding time points to the influenza
A(H1N1) virus (r = 0.68; P = .0004) and influenza A(H3N2)
virus (r = 0.47; P = .0189) strains but not to the influenza B
virus strain.
To see whether previous infection (priming status) of the
subjects influenced their short-term MBC response after
LAIV vaccination, we stratified each individual on the basis of
their prevaccination serological titer as primed (HI titer of ≥40)
or naive (unprimed; HI titer of <40; Figure 5). The primed sub-
jects had significantly higher IgG MBC frequencies than the
naive subjects against influenza A(H1N1) virus in both tonsils
(mean, 469 and 51 MBCs/106 TMCs, respectively) and blood
(mean, 1100 and 130 MBCs/106 PBMCs, respectively) and
against the influenza A(H3N2) virus strain in tonsils (mean,
Figure 3. The immunoglobulin A (IgA) response in saliva after live attenuated influenza vaccine (LAIV) vaccination. Saliva samples were collected from nonvaccinated
controls (open circles) and LAIV recipients (closed circles) on the day of tonsillectomy (day 3, 7, or 14) and 28–180 days after vaccination. The IgA antibody levels in saliva
were determined by enzyme-linked immunosorbent assay for each strain A (H1N1), B (H3N2), and C (B strain). Each symbol represents the IgA response of 1 subject, with
means and standard errors of the mean indicated. Statistical significance between prevaccination and postvaccination responses was measured by the nonparametric Kruskal–
Wallis multiple comparisons test. *P < .05 and **P≤ .01.











710 and 182 MBCs/106 TMCs, respectively). Low frequencies of
MBCs were observed for the influenza B virus strain in the un-
primed children, and generally a higher response was observed
in the primed child (only 1 of the 4 primed children had results
for the B strain). No significant differences in influenza virus–
specific IgA and IgM MBC responses were observed between
primed and naive individuals (data not shown).
We have earlier shown that LAIV significantly increases
MBC responses in these children, which persist for up to 6–
12 months [13]. When we analyzed these long-term IgG
Figure 4. Antibody-secreting cell (ASC) response in tonsils and peripheral blood after live attenuated influenza vaccine (LAIV) vaccination. Children were vaccinated with
2012–2013 seasonal LAIV, and the immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) ASC responses in tonsillar mononuclear cells (TMCs) and
peripheral blood mononuclear cells (PBMCs) were measured by enzyme-linked immunospot assay. The influenza virus–specific IgG (A), IgA (B), and IgM (C) ASC responses
against a combination of the 3 viruses (influenza A(H1N1), A(H3N2), and B viruses) were determined in TMCs isolated from nonvaccinated controls (open circles) and LAIV
recipients (closed circles) 3, 7, and 14 days after vaccination. The IgG (D), IgA (E ), and IgM (F ) ASC responses against a combination of 3 influenza viruses (influenza A(H1N1), A
(H3N2), and B viruses) were measured in PBMCs isolated before vaccination (day 0) and at 3, 7, 14, and 28 days after vaccination. A–F, Each symbol represents influenza virus–
specific ASCs per 1 × 106 cells with mean ± standard error of the mean indicated. Statistical differences between vaccinated and nonvaccinated subjects were determined by
the nonparametric Kruskal–Wallis multiple comparisons test. *P < .05, **P≤ .01, and ****P≤ .0001.











MBC responses (up to day 180) according to the priming
status, we found a significant increase in MBCs in the unprimed
children after LAIV vaccination and not in the primed children
(Figure 6A–6C). This indicates that the increase in the MBC re-
sponse after LAIV vaccination was largely influenced by the
priming status of the child.
DISCUSSION
Tonsils represent both an induction and maintenance site for
mucosal immune responses in the nasopharynx against respira-
tory pathogens (ie, influenza virus) encountered through natu-
ral infection [22]. However, limited data are available on the
tonsillar role and contribution to the local immune response
Figure 5. The short-term effect of priming on memory B-cell (MBC) response in tonsils and blood after live attenuated influenza vaccine (LAIV) vaccination. The children were
classified as “primed” if they had a hemagglutination inhibition (HI) antibody titer of ≥40 and as “naive” if the HI titer was <40 prior to vaccination. The figure shows the
influenza A(H1N1) virus–specific (A), influenza A(H3N2) virus–specific (B), and influenza B virus–specific (C) immunoglobulin G (IgG) MBC response in tonsillar mononuclear
cells (TMCs). The IgG MBC results for the 3 strains in peripheral blood mononuclear cells (PBMCs) are shown in panels D–F from primed and naive subjects. Each symbol
represents the MBC response of 1 subject, and the horizontal lines represent the means ± standard errors of the mean indicated. Statistical differences between the primed and
naive groups were measured by the Mann–Whitney nonparametric test. **P≤ .01 and ***P≤ .001.











after intranasal vaccination. In this unique study, we were able
to collect tonsils, saliva, and blood samples from young children
(median age, 4 years) who were intranasally vaccinated with a
LAIV prior to elective tonsillectomy. These pediatric samples
enabled us to assess the local lymphoid and saliva responses,
as well as the systemic immune responses.
The immune responses elicited by LAIV are multifaceted,
similar to those after natural infection. The induction of ade-
quate immune responses to LAIV is dependent on local replica-
tion of the virus, and hence preexisting mucosal antibodies may
reduce viral replication. Protection after LAIV is thought to be
associated with induction of mucosal antibodies, but challenges
in sampling and assaying these antibodies have hampered de-
velopment of mucosal antibodies as a correlate of protection
[2]. IgA is the predominant secreted antibody at mucosal surfac-
es [23, 24].We detected elevated IgA levels in saliva 14 days after
vaccination, and the response persisted in some subjects for 180
days, which is similar in duration to the nasal IgA response ob-
served after LAIV vaccination in children [8, 25]. This indicates
that the mucosal immune response is well developed in young
children and that the LAIV provides local protection in the
nasal and oral cavities. Importantly, a significant positive asso-
ciation was observed between the influenza virus–specific sali-
vary IgA and serum antibody responses. This implies that
salivary IgA levels could be a possible noninvasive biomarker
to predict the immunogenicity of LAIV and could be particular-
ly useful when assessing the effectiveness of the vaccine in
children.
The LAIV enhanced the systemic antibody responses toward
the influenza A(H3N2) and B virus strains in most subjects, but
no boost was observed against the influenza A(H1N1) virus
strain. A lack of measurable effectiveness against the influenza
A(H1N1) virus strain in the 2013 LAIV has been reported in the
United States, and the LAIV is no longer the sole recommended
vaccine for children [26–28]. The LAIV influenza A(H1N1)
virus strain had reduced viral fitness due to temperature insta-
bility, and the vaccine manufacturer has developed a new influ-
enza A(H1N1) virus strain to overcome these problems [29].
However, the preexisting antibodies to influenza A(H1N1)
virus may have also contributed to the low effectiveness, since
most children had previously been infected or vaccinated with
this strain during the 2009 pandemic.
The humoral immune response was further characterized by
analyzing the ASC responses in the tonsils and blood. Our ear-
lier work in adults has shown that after intramuscular TIV vac-
cination, antigen-specific ASC responses appear transiently in
the blood. These ASCs peak 1 week after vaccination, correspond-
ing to the peak plasmablast (CD19+CD20−CD27highCD38high)
response [14, 19]. The kinetics of the circulating ASC response
was slower after LAIV vaccination as compared to TIV vaccina-
tion, with the highest response observed 2 weeks after vaccination.
The extended ASC response after intranasal immunization could
be due to longer persistence of the vaccine viruses. Data from re-
spiratory syncytial virus–infected subjects show that ASCs are pro-
duced for as long as the virus is shed [30]. An extended ASC
response was also detected in the tonsils; however, we cannot
Figure 6. The long-term effect of priming on memory B cells (MBCs) in blood
after live attenuated influenza vaccine (LAIV) vaccination. The children were classi-
fied as “primed” if they had a hemagglutination inhibition (HI) antibody titer of ≥40
and as “naive” if the HI titer was <40 prior to vaccination. The immunoglobulin G
(IgG) MBC results for the 3 strains were measured in peripheral blood mononuclear
cells (PBMCs) isolated before vaccination (day 0) and 28, 56, and 180 days after vac-
cination (A–C). Each symbol represents influenza virus–specific MBCs per 1 × 106
cells with mean ± standard error of the mean indicated. Statistical differences be-
tween the different time points and day 0 were determined by the nonparametric
Kruskal–Wallis multiple comparisons test. *P < .05, **P ≤ .01, and ***P ≤ .001,
respectively.











rule out a peak later than our last sampling point (day 14). In the
tonsils, the predominant influenza virus–specific responses were
unswitched IgM ASCs, which indicates activation of naive B-cell
responses to novel epitopes on the viral surface glycoproteins. Rel-
atively low IgA responses were observed in tonsils after LAIV vac-
cination, in agreement with our previous observation in children
after TIV vaccination [15]. Although the number of influenza
virus–specific IgG and IgAASCs remained relatively low in tonsils,
compared with blood, it still represents a significant immunolog-
ical response, as >109 cells were isolated from some tonsils.
Recall antibody responses produced by MBCs are crucial for
influenza vaccine–induced protective immunity. We observed
influenza virus–specific MBCs in both tonsils and blood before
vaccination in most children. The presence of tonsillar MBCs
could be a significant factor in providing long-term protection
at the site of initial virus infection in the upper respiratory tract, as
murine studies have shown that long-lived antibody responses
against viruses originate from existing MBCs [31]. The impor-
tance of mucosal MBCs in protective immunity is highlighted
by the fact that at baseline, primed subjects had significantly high-
er influenza virus–specific IgG MBCs in their tonsils than un-
primed subjects. The MBCs measured at day 0 or in the
controls reflected prior infection history. The observation of
high levels of influenza A(H1N1) virus– and A(H3N2) virus–spe-
cific MBCs in some of the control children in both tonsils
and blood (Supplementary Figure 1) is probably a result of earlier
infection by the circulating influenza A(H1N1) or A(H3N2) virus
strains, not previous vaccination, as influenza vaccination is only
recommended for children with high-risk conditions in Norway.
We observed interstrain differences in the immune response
after LAIV vaccination, with the influenza B virus strain inducing
the highest antibody responses both locally (saliva and tonsils)
and systemically (blood). Most of the children were naïve to the
influenza B virus strain; nonetheless, the majority reached protec-
tive HI titers 14 days after vaccination, indicating a rapid induc-
tion of protective antibody. Although individual variance will
affect the kinetics of the immune response, the results from our
study may represent different types of immune responses: an
experienced population (with the majority previously exposed
to influenza A(H1N1) virus) and a naïve population (with the
majority without prior influenza A(H3N2) and B virus strain
exposure).
Importantly, there was a significant positive correlation be-
tween influenza virus–specific tonsillar IgG MBC responses
and serum HI titers, which is consistent with findings that
IgG MBCs are more likely to become plasmablasts that appear
in the circulation, capable of producing influenza virus–specific
antibody responses [32–34].Although the early influenza virus–
specific MBC responses were not boosted by vaccination within
the 2-week period (Supplementary Figure 1), the MBC respons-
es increased in blood by 28–56 days after vaccination, lasting up
to 12 months [13]. Importantly, our results show that the
increased MBC responses after LAIV occur mainly in unprimed
(naïve) children (Figure 6).
MBC responses are rapid, producing more high-affinity anti-
bodies than naïve B cells. The primed children had higher MBC
levels, which were not boosted further after LAIV vaccination,
possibly because a threshold level was reached (Figure 6), which
has been observed by Sasaki et al [16]. LAIV may however help
maintenance and maturation of the MBC response, producing
antibodies with a broader repertoire to influenza virus [35]. The
finding that primed children had a greater IgG MBC response
in both tonsils and blood toward the 2 influenza A virus strains
(Figure 5) could therefore suggest that a more mature immune
response is achieved in these children. This is supported by ear-
lier studies showing that serum IgG levels induced after influen-
za virus infection or vaccination are correlated with resistance to
infection [26], with higher antibody levels with increased avid-
ity. The lack of correlation between influenza B virus strain se-
rological titers and IgG MBCs could indicate that the influenza
B virus strain kinetics are different or that the response arises at
a later time point, as the vast majority were naïve to this strain.
Only the naïve children showed a significantly increased long-
term MBC response in blood beyond the time points we sam-
pled the tonsils (Figure 6). The weaker influenza A(H1N1) virus
strain [29] did not boost the MBC response, but the influenza
A(H3N2) and B virus strains elicited boosted MBCs responses
in naïve children, and the majority seroconverted. Our findings
support European recommendations of LAIV vaccination by
children only and can explain the lower effectiveness of LAIV
found in adults as compared to children. Our study is limited
by the small number of subjects and because we asked the par-
ents about influenza illnes in their children but did not test the
children during the trial.
Future studies may elucidate the ability of LAIVs to induce
cross-reactive antibodies and cellular immunity. In the present
study, we are the first to show that vaccination with a mucosal
influenza vaccine enhances antibody and B-cell immune re-
sponses in palatine tonsils. Better understanding of the tonsillar
immune responses will aid the development of vaccination
strategies aimed at enhancing local immunity against influenza.
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